Back to Search
Start Over
Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.
- Source :
-
BMC cancer [BMC Cancer] 2018 Oct 16; Vol. 18 (1), pp. 983. Date of Electronic Publication: 2018 Oct 16. - Publication Year :
- 2018
-
Abstract
- Background: Indirect evidence suggesting the immunosensitivity/immunogenicity of neuroblastoma is accumulating. The aims of this study were to investigate the immune landscape of neuroblastoma and to evaluate the in vivo immunogenicity of the NY-ESO-1 tumor antigen in advanced neuroblastoma patients.<br />Methods: The immune infiltrating cells of the NY-ESO-1+ tumors from three HLA*A201 patients with metastatic neuroblastoma who relapsed after conventional treatments were evaluated by immunohistochemistry. The patients were vaccinated with the HLA-A*0201-restricted peptide NY-ESO-1 <subscript>157-165(V)</subscript> . The peptide was emulsified in Montanide ISA51 and given subcutaneously in a phase I pilot study. The immunogenicity of NY-ESO-1 antigen was evaluated by monitoring mononuclear cells in patient peripheral blood, pre- and post-vaccine, by short-term in vitro sensitization, HLA-multimer staining and IFN-γ ELISpot analysis.<br />Results: Both CD3 T cells and CD163 myeloid cells were present in pre-vaccine tumors and PD-1 and PD-L1 expression was mainly found in the immune infiltrate. Despite the advanced stage of the disease, the vaccination induced systemic NY-ESO-1 specific CD8 T cells releasing IFN-γ in response to activation with the NY-ESO-1 peptide and an HLA-A2 positive neuroblastoma cell line.<br />Conclusions: Our results indicate that vaccination with a tumor-associated peptide is able to boost NY-ESO-1-specific, functionally active T cells in advanced neuroblastoma patients with lymphocyte infiltration in their pre-vaccine tumors.<br />Trial Registration: EudraCT #2006-002859-33.
- Subjects :
- Antigens, Neoplasm therapeutic use
Child, Preschool
Female
Humans
Immunotherapy, Active
Lymphocytes, Tumor-Infiltrating immunology
Membrane Proteins therapeutic use
Neuroblastoma pathology
T-Lymphocyte Subsets immunology
Antigens, Neoplasm immunology
Cancer Vaccines
Immunogenicity, Vaccine
Membrane Proteins immunology
Neuroblastoma immunology
Neuroblastoma therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2407
- Volume :
- 18
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC cancer
- Publication Type :
- Academic Journal
- Accession number :
- 30326856
- Full Text :
- https://doi.org/10.1186/s12885-018-4910-8